New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For LLY;PFE;ACTC;CYTX;STEM;ATHX;LH;OVSC;NBS;PSTI;FLDM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | all recent news | >>
July 27, 2015
18:30 EDTPFEAllergan CEO pursuing 'transformational deals,' FT says
In a Financial Times interview following the sale of its generics unit to Teva (TEVA), Allergan's (AGN) CEO Brent Saunders stated, "We’re going to contemplate transformational deals... We couldn’t before because of our capital structure and debt, but now we can." When asked about the timing of a potential deal, Saunders remarked, "We’re not going to plod along," and when asked about a hypothetical takeover by Pfizer (PFE), the CEO commented, "I spend zero time thinking about Pfizer and I am not doing anything to make us more or less attractive to them." Reference Link
16:00 EDTPFEOptions Update; July 27, 2015
Subscribe for More Information
15:03 EDTPFE, LHNotable companies reporting before tomorrow's open
Subscribe for More Information
12:36 EDTPFEEarnings Watch: Pfizer shares nearly flat since last earnings report
Subscribe for More Information
08:08 EDTLLYEli Lilly accepts recommendation to continue Phase 3 trial of evacetrapib
Subscribe for More Information
05:38 EDTPSTIPluristem says new data shows PLX cells regulate immune system
Pluristem Therapeutics announced the publication of a scientific study regarding PLacental expanded, or PLX, cells in the prominent peer-reviewed journal Stem Cells. The paper, titled "Mesenchymal stromal cells prevent allostimulation in vivo and control checkpoints of Th1 priming: migration of human DC to lymph nodes and NK cell activation", describes the findings of a recent mechanism of action study conducted by independent scientists at the Berlin-Brandenburg Center for Regenerative Therapy at Charité - University Medicine Berlin. The paper was co-authored by scientists from the Charité and Pluristem. The study demonstrated mechanisms by which PLX cells and other mesenchymal stromal cells, or MSC, influence the immune system in order to modulate immune reactions and to prevent immune reactions against the cells when they are administered as an off-the-shelf product. It was demonstrated in vitro that MSC, and in particular PLX cells, control the induction of an immune response at several points. The main target for MSC and PLX cells in this process are dendritic cells, which are the key player in inducing a T-cell immune response. Moreover, in vivo data from patients suffering from critical limb ischemia who were treated with PLX cells in a phase I/II study confirmed that HLA-unmatched PLX cells did not provoke an immune response in immunocompetent patients. These findings confirm the feasibility of using PLX cells in an off-the-shelf manner, and explain the mechanisms that make this possible.
July 24, 2015
09:33 EDTLLYEli Lilly weakness creates buying opportunity, says Argus
Subscribe for More Information
July 23, 2015
13:44 EDTSTEMStemCells says patent infringement case against Neuralstem dismissed by court
Subscribe for More Information
10:08 EDTLLYOptions with decreasing implied volatility
Subscribe for More Information
09:25 EDTFLDMFluidigm discloses CEO had violated conflict of interest provision
Subscribe for More Information
08:43 EDTLLYEli Lilly Alzheimer's data positive, says SunTrust
Subscribe for More Information
07:49 EDTSTEMNeuralstem awarded favorable court ruling in StemCell patent litigation
Subscribe for More Information
06:48 EDTLLYEli Lilly up 5.5% after reporting Q2 results, raising FY15 guidance
06:37 EDTLLYEli Lilly expands San Diego biotechnology center
Subscribe for More Information
06:33 EDTLLYEli Lilly raises FY15 EPS view to $3.20-$3.30 from $3.10-$3.20, consensus $3.18
Narrows FY15 revenue guidance to $19.7B-$20B from $19.5B-$20B, consensus $19.8B.
06:30 EDTLLYEli Lilly reports Q2 adjusted EPS 90c, consensus 74c
Subscribe for More Information
July 22, 2015
15:26 EDTLLYNotable companies reporting before tomorrow's open
Subscribe for More Information
10:59 EDTLLYBiogen drops after reporting data on Alzheimer's drug
The shares of Biogen (BIIB) are falling after the company released data on its Alzheimer's treatment candidate, aducanumab. Peer Eli Lilly (LLY) also reported data this morning on its own experimental Alzheimer's drug, solanezumab. BIOGEN: Biogen's data "does not inspire confidence," Piper analyst Joshua Schimmer wrote in a note to investors today. The 6 mg dose of the drug performed similarly to the 1mg dose, and was barely better than the placebo, the analyst stated. The cognitive and functional performance of the patients who took the 6 mg dose did not improve by a statistically significant amount, while the results of patients taking the other doses were "noisy,"Schimmer stated. Additionally, indications of excess fluid in the brain was observed in a significant number of patients, representing an additional problem for the treatment, the analyst believes. The data "is far from inspiring confidence" and makes the outlook for aducanumab "more speculative than ever," Schimmer contended. LILLY: Also this morning, Eli Lilly presented results from a pre-specified secondary analysis of several Phase 3 studies at the Alzheimer's Association International Conference. According to the company, the results suggest the treatment effect of solanezumab was preserved within a pre-specified amount in patients with mild Alzheimer's disease who received solanezumab earlier in the disease compared to patients who began treatment at a later point. Treatment differences in cognition and function between early-start and delayed-start groups at the end of the placebo-controlled period were preserved at the primary time point of 108 weeks within a pre-defined margin. Treatment differences in cognition and function between early-start and delayed-start groups at the end of the placebo-controlled period were also preserved at an additional time point of 132 weeks within a pre-defined margin.The differences at 108 weeks and at at 132 weeks remained statistically significant, the company said. PRICE ACTION: In morning trading, Biogen fell 3% to $397.43 while Eli Lilly shares rose 0.6% to $86.11.
10:05 EDTLLYEli Lilly gaps down, retraces, levels to watch
Subscribe for More Information
08:40 EDTLLYEli Lilly July weekly volatility elevated into Q2 and Alzheimer's drug data
Subscribe for More Information
08:32 EDTPFEPfizer expands lease agreement with MIT subsidiary
Subscribe for More Information
07:18 EDTLLYEli Lilly drops 3% to $83 after reporting Alzheimer's drug data
Subscribe for More Information
07:06 EDTLLYEli Lilly's solanezumab for Alzheimer's supports 'delayed-start' use
Subscribe for More Information
July 21, 2015
08:04 EDTPFEPfizer launches Caltrate Bone & Joint Health supplement
Pfizer Consumer Healthcare announced the launch of Caltrate Bone & Joint Health, a 3-in-1, triple action product that delivers UC-II, an exclusive form of collagen, to support healthy cartilage and promote joint flexibility, calcium and vitamin D3, to nourish strong and healthy bones, and vitamin C and minerals to support collagen production for healthy bones and skin.
July 20, 2015
08:12 EDTSTEMStemCells transplants first patient in clinical trial for macular degeneration
StemCells announced that it has completed transplantation of the first subject in its Radiant Study at the Retina Foundation of the Southwest. The Phase II trial is designed to evaluate both the safety and efficacy of the company's proprietary HuCNS-SC platform technology for the treatment of geographic atrophy, the most advanced form of dry age-related macular degeneration
07:33 EDTSTEMInternational AIDS Society to hold a conference
Subscribe for More Information
07:32 EDTLLYAlzheimer's Association to hold a conference
Subscribe for More Information
July 16, 2015
16:00 EDTPFEOptions Update; July 16, 2015
iPath S&P 500 VIX Short-Term Futures down 1.17 to 16.52 Option volume leaders: NFLX AAPL BAC FB F INTC C EBAY AMZN GM JPM MU PFE BABA JD X
July 15, 2015
10:01 EDTLLYOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:04 EDTPFEPfizer treatment of CIDP granted FDA orphan status
Subscribe for More Information
06:37 EDTLLYEli Lilly downgraded to Equal Weight from Overweight at Morgan Stanley
Subscribe for More Information
July 14, 2015
10:22 EDTPFEEuropean Commission says Pfizer offers concessions for Hospira deal, Reuters say
Subscribe for More Information
July 13, 2015
12:01 EDTFLDMFluidigm and OpGen enter into agreement to develop resistance testing kits
Subscribe for More Information
11:47 EDTLLY, PFEFDA approves new drug to treat schizophrenia
The U.S. FDA announced that it has approved Rexulti tablets to treat adults with schizophrenia and as an add-on treatment to an antidepressant medication to treat adults with major depressive disorder. Rexulti is manufactured by Tokyo-based Otsuka Pharmaceutical. Novartis' (NVS) Clozaril is indicated to treat severely ill adult patients with schizophrenia who have not responded appropriately to standard antipsychotic treatment. Other atypical antipsychotics include Otsuka's Abilify, Pfizer's (PFE) Geodon, Janssen's (JNJ) Invega and Risperdal, Forest Labs' (ACT) Saphris, AstraZeneca's (AZN) Seroquel and Eli Lilly's (LLY) Zyprexa.
07:44 EDTLLY, PFEEli Lilly price target raised to $105 from $100 at Jefferies
Subscribe for More Information
<< 1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use